Measles in Bangladesh: A Preventable Disease Threatening Thousands of Children
Published April 2026 | Health Awareness | Read time: ~8 minutes
Introduction: A Crisis That Should Not Exist
In early 2026, Bangladesh found itself at the center of a public health emergency that shocked the nation — a massive measles outbreak spreading across 58 of its 64 districts, claiming the lives of children who should have been protected by a simple, safe, and effective vaccine.
Measles, locally known as হাম (Ham), is not a new disease. It has plagued humanity for centuries. Yet in 2026, as Bangladesh reported over 23,000 suspected cases and nearly 200 deaths — the vast majority of them children under five — the world was reminded of a sobering truth: a disease we can prevent can still devastate a nation when health systems falter.
This blog post provides a comprehensive look at measles — what it is, how it spreads, its symptoms and complications, and why Bangladesh is facing this crisis right now. Whether you are a concerned parent, a healthcare professional, or a student of public health, this is essential reading.
What is Measles? Understanding the Disease
Measles is a highly contagious viral infection caused by the Rubeola virus (genus Morbillivirus, family Paramyxoviridae). It is an RNA virus that infects only humans — no animal reservoir exists — making it theoretically eliminable through vaccination alone.
How contagious is it?
Measles is considered one of the most infectious diseases ever identified. Its basic reproductive number (R₀) is 12–18, meaning a single infected person can transmit the virus to 12 to 18 unvaccinated individuals in a susceptible population. For comparison, COVID-19's original R₀ was estimated at 2–3, and seasonal influenza at 1.2–1.4.
The virus spreads through airborne respiratory droplets — when an infected person coughs or sneezes, viral particles remain suspended in the air and on surfaces for up to two hours after they have left the room. Touching a contaminated surface and then touching the mouth, nose, or eyes can also transmit the disease.
A critical and often overlooked fact: an infected person is contagious from four days before to four days after the rash appears — meaning the disease spreads before most people even know they have it.
Signs and Symptoms: What to Watch For
Measles symptoms do not appear all at once. The disease progresses in distinct stages, typically over 7–10 days.
Stage 1 — Prodromal Phase (Days 1–4)
- High fever (can reach 40.6°C / 105°F)
- Persistent cough
- Runny nose (coryza)
- Red, inflamed, watery eyes (conjunctivitis)
- Koplik's spots — tiny white spots with a bluish tinge inside the cheeks; these are pathognomonic (uniquely characteristic) of measles and appear 2–3 days before the rash
Stage 2 — Rash Phase (Days 3–7)
- A blotchy, flat rash appears first on the face and hairline, then spreads downward to the neck, chest, back, arms, and finally the feet
- On lighter skin, the rash appears red; on darker skin, it may appear purple or darker than surrounding skin
- Fever typically spikes again with the onset of the rash
- The rash usually lasts 5–7 days
Recovery
If uncomplicated, most healthy individuals begin recovering after 7–10 days. However, measles also causes immune amnesia — temporarily weakening the immune system for months after infection, making the patient vulnerable to other illnesses.
Dangerous Complications: When Measles Turns Deadly
While many people associate measles with a mild childhood rash, the reality is far more serious. Complications can arise in any patient but are most severe in:
- Children under 5 years of age
- Malnourished children, especially those with Vitamin A deficiency
- Pregnant women
- People with weakened immune systems
Serious complications include:
| Complication | Notes |
|---|---|
| Pneumonia | Leading cause of measles-related death |
| Encephalitis | Brain inflammation; affects ~1 in 1,000 cases |
| Blindness | A leading cause of preventable blindness in children |
| Severe diarrhoea & dehydration | Especially dangerous in young children |
| Ear infections | Can lead to permanent hearing loss |
| Subacute Sclerosing Panencephalitis (SSPE) | A rare but fatal neurological disorder developing years after infection |
Globally, 1–3 children per 1,000 infected die from measles complications. In countries with high rates of malnutrition and low healthcare access, like parts of Bangladesh, this rate is significantly higher.
Diagnosis and Treatment
Diagnosis
Measles is typically diagnosed clinically — a physician can often identify it from the characteristic combination of fever, rash, cough, runny nose, and red eyes. Koplik's spots, when present, are a near-definitive clinical sign.
Laboratory confirmation involves:
- Nasal or throat swab (preferred)
- Blood test for measles IgM antibodies
- Virus isolation and genotyping (used for outbreak surveillance)
Treatment: Supportive Care Only
There is currently no specific antiviral treatment for measles. Management focuses on:
- Rest and hydration to prevent dehydration
- Fever management using paracetamol or ibuprofen (never aspirin in children — risk of Reye's syndrome)
- Vitamin A supplementation — WHO recommends two doses for all children with measles; reduces severity and risk of blindness significantly
- Antibiotics only if secondary bacterial infections (e.g., pneumonia, ear infection) develop
Hospitalisation may be required for severe cases or at-risk patients.
Bangladesh's Vaccination History: From Success to Crisis
Bangladesh's immunisation story is one of remarkable achievement — and a cautionary tale about the fragility of public health gains.
The Rise of EPI (1979–2016)
The Expanded Programme on Immunisation (EPI) was launched on April 7, 1979, as a pilot project in eight thanas across four divisions. By 1985, Bangladesh committed to the Global Universal Child Immunisation Initiative and expanded EPI nationwide.
Over the following decades, measles vaccination coverage grew dramatically:
- MR1 (first dose) coverage rose from 89% in 2000 to a remarkable 118% in 2016
- MR2 (second dose) grew from 22% in 2012 (when it was introduced) to 121% by 2024
- In 2014, a nationwide SIA (Supplementary Immunisation Activity) reached 53.6 million children across 63 of 64 districts
- By 2015, Bangladesh had established a National Verification Committee for Measles Elimination
Bangladesh was, by all measures, a global model for immunisation success in South Asia.
The Decline (2020–2025)
Then things began to unravel — quietly at first, then catastrophically:
- 2020: The last nationwide measles-rubella supplementary campaign was held. No follow-up SIA was conducted for the next five years.
- 2023: The Coverage Evaluation Survey showed MR1 at 86% (down from 88.6%) and MR2 at 80.7% (down from 89%) — far below the 95% threshold needed for herd immunity.
- 2024: A planned nationwide vaccination campaign was cancelled due to the political uprising that toppled Prime Minister Sheikh Hasina.
- 2024–2025: A nationwide stockout of the MR vaccine prevented routine immunisation for thousands of children.
The result: an estimated 10 million children susceptible due to MR1 gaps, and a staggering 20 million susceptible due to MR2 gaps.
The 2026 Outbreak: What Happened?
On March 15, 2026, cases began escalating rapidly. By April 4, Bangladesh officially notified WHO of a nationwide outbreak. The scale was alarming:
- 23,606+ suspected cases and 2,897 laboratory-confirmed cases (as of late April 2026)
- 194 suspected deaths and 39 confirmed deaths
- 58 of 64 districts affected across all 8 divisions
- 79% of cases among children under 5 years
- 91% of cases among children aged 1–14 years
- Dhaka Division recorded the highest toll — 25 confirmed deaths and 90 suspected deaths
WHO officially assessed the national risk as HIGH, noting that "the outbreak suggests a reversal from Bangladesh's previous progress towards measles elimination."
For context: only 125 measles cases were recorded in all of Bangladesh in 2025.
Root Causes
The outbreak was not caused by any single factor but by a convergence of failures:
- Vaccine stockout (2024–25) — disrupted routine immunisation
- Cancelled 2024 campaign — political instability prevented planned SIA
- No supplementary campaigns since 2020 — 5+ years of accumulating susceptibility
- Vaccine misinformation — growing hesitancy among some parents
- EPI funding structure — ~70% donor-dependent; vulnerable to external disruptions
- High population density — 1,333 people/km² accelerates transmission
The Emergency Response
Bangladesh moved swiftly once the scale of the outbreak became clear:
- April 5, 2026: Emergency MR vaccination campaign launched in 30 upazilas of 18 priority districts, targeting children aged 6–59 months regardless of prior vaccination status
- Prime Minister Tarique Rahman lowered the vaccination eligibility age from 9 months to 6 months
- April 20, 2026: Campaign expanded nationwide to all remaining districts
- By April 19: Over 1.6 million children vaccinated — 73% of the initial target
- Vitamin A supplementation provided to all suspected and confirmed cases
- District Rapid Response Teams activated; WHO SIMOs deployed nationally
- UNICEF, WHO, and Gavi providing coordinated technical and financial support
What Healthcare Professionals and Researchers Should Know
For clinicians and public health researchers, the Bangladesh 2026 outbreak carries several important lessons:
Clinical considerations
- Infants 6–9 months are a newly vulnerable group in this outbreak — maternal antibody protection wanes earlier than expected in populations with low seroprevalence mothers
- Vitamin A deficiency must be assessed and treated in all suspected measles cases — WHO recommends two doses on consecutive days for children 12 months and older
- Post-measles immune suppression can last 2–3 years — monitor recovered patients for opportunistic infections
Epidemiological insights
- The outbreak demonstrates how 5+ years without SIAs can reverse decades of immunisation progress
- Genotyping data from Bangladesh (initiated in 2014) is critical for tracking viral lineages and cross-border transmission
- Immune amnesia caused by measles may have broader population-level immunity consequences beyond the measles cases themselves
Research gaps
- Impact of vaccine hesitancy on coverage in urban Bangladesh
- Cross-border transmission dynamics with India and Myanmar
- Long-term neurological outcomes (SSPE) from this outbreak cohort
Prevention: What You Can Do
The measles-rubella (MR) vaccine remains the single most powerful tool against this disease.
For parents:
- Ensure your child receives MR1 at 9 months and MR2 at 15 months
- During the current outbreak, bring children aged 6 months to 5 years to the nearest EPI centre for the emergency campaign dose — it is free
- Do not delay vaccination based on misinformation — the MR vaccine is extensively tested, safe, and effective
- Ensure adequate Vitamin A in your child's diet (found in eggs, dairy, orange/yellow vegetables, leafy greens)
For the community:
- Share accurate information; counter measles myths on social media
- Encourage neighbours, particularly in rural or hard-to-reach areas, to vaccinate their children
- Report suspected cases early to local health authorities
Conclusion: A Preventable Tragedy
The 2026 measles outbreak in Bangladesh is not simply a disease story — it is a story about what happens when immunisation systems are neglected, when political disruption interrupts health programmes, when supply chains break down, and when misinformation fills the vacuum left by under-resourced health communication.
Bangladesh achieved remarkable things with its EPI programme. It showed the world that even a low-income, densely populated country could bring a dangerous disease to the brink of elimination. The 2026 outbreak does not erase that achievement — but it does demand that the lesson be learned: immunisation progress is fragile, and it requires continuous investment, political commitment, and community trust to sustain.
Every child who died in this outbreak did not have to. Every child who will be vaccinated in the coming weeks represents a life defended against a disease that we have had the tools to prevent for over 50 years.
The vaccine exists. The knowledge exists. The will to act must exist too.
Key Facts at a Glance
| Fact | Detail |
|---|---|
| Causative virus | Rubeola virus (Morbillivirus) |
| Reproductive number (R₀) | 12–18 |
| Incubation period | 7–14 days |
| Infectious period | 4 days before to 4 days after rash |
| Vaccine doses needed | 2 (MR1 at 9 months, MR2 at 15 months) |
| Vaccine effectiveness | ~85% (1 dose), ~95% (2 doses) |
| Herd immunity threshold | ≥95% population coverage |
| 2026 Bangladesh cases | 23,606+ suspected; 2,897 confirmed |
| 2026 Bangladesh deaths | 194 suspected; 39 confirmed |
| Districts affected (2026) | 58 of 64 |
| Emergency campaign target | Children 6–59 months |
References & Further Reading
- WHO Disease Outbreak Notice DON598 — Bangladesh, April 2026
- UNICEF Bangladesh — FAQ on Measles Outbreak, April 2026
- CDC MMWR — Progress Toward Measles Elimination: Bangladesh, 2000–2016
- PMC — Molecular Detection and Genetic Diversity of Measles Virus in Bangladesh, 2026
- WHO — Measles Vaccines: Position Paper, 2023
- Bangladesh Directorate General of Health Services (DGHS) — Situation Reports, 2026
This blog post is written for informational and educational purposes. If you suspect measles in yourself or a child, contact your nearest health facility immediately. For vaccination, visit your nearest EPI centre — the MR vaccine is free in Bangladesh.